NCT04499859View on ClinicalTrials.gov

Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI

PHASE4RecruitingINTERVENTIONAL
Enrollment

3,548

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2027

Conditions
Myocardial InfarctionStatin Adverse ReactionHMG-CoA Reductase Inhibitor Toxicity
Interventions
DRUG

Ezetimibe 10mg + Rosuvastatin 5mg

Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin

DRUG

Rosuvastatin 20mg

20mg of Rosuvastatin as a standard treatment for AMI patients

Trial Locations (7)

Unknown

RECRUITING

Bucheon St.Mary Hospital, Bucheon-si

RECRUITING

St.Vincent's Hospital, Suwon

RECRUITING

Uijeongbu St.Mary's Hospital, Uijeongbu-si

RECRUITING

Daejeon St.Mary's Hospital, Daejeon

RECRUITING

Incheon St.Mary's Hospital, Incheon

RECRUITING

Yeouido St.Mary Hospital, Seoul

137-701

RECRUITING

Seoul St.Mary's Hospital, Seoul

All Listed Sponsors
lead

Kiyuk Chang, MD,PhD

OTHER